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Long-term survival in multiple myeloma is associated with
a distinct immunological proﬁle, which includes proliferative
cytotoxic T-cell clones and a favourable Treg/Th17 balance
C Bryant1,2,3, H Suen1,4, R Brown1, S Yang1, J Favaloro1, E Aklilu1, J Gibson1, PJ Ho1, H Iland1, P Fromm2,3, N Woodland4, N Nassif4,
D Hart2,3 and DE Joshua1,3
Despite improved outcomes in multiple myeloma (MM), a cure remains elusive. However, even before the current therapeutic era,
5% of patients survived 410 years and we propose that immune factors contribute to this longer survival. We identiﬁed patients
attending our clinic, who had survived 410 years (n¼ 20) and analysed their blood for the presence of T-cell clones, T-regulatory
cells (Tregs) and T helper 17 (Th17) cells. These results were compared with MM patients with shorter follow-up and age-matched
healthy control donors. The frequency of cytotoxic T-cell clonal expansions in patients witho10 years follow-up (MM patients) was
54% (n¼ 144), whereas it was 100% (n¼ 19/19) in the long-survivors (LTS-MM). T-cell clones from MM patients proliferated poorly
in vitro, whereas those from LTS-MM patients proliferated readily (median proliferations 6.1% and 61.5%, respectively (Po0.0001)).
In addition, we found signiﬁcantly higher Th17 cells and lower Tregs in the LTS-MM group when compared with the MM group.
These results indicate that long-term survival in MM is associated with a distinct immunological proﬁle, which is consistent with
decreased immune suppression.
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INTRODUCTION
Before the introduction of immunomodulatory agents and
proteasome inhibitors, less than 5% of patients with multiple
myeloma (MM) survived for longer than 10 years. Attempts to
identify factors associated with prolonged survival, arbitrarily set
at 10 years, suggested younger age, lower tumour mass and
response to therapy.1–4 The ability to achieve disease control with
allogeneic transplantation5 and donor lymphocyte infusions6
indicates the potential for immune-mediated control in patients
with MM. There is also indirect evidence of host anti-tumour
immune activity through the identiﬁcation of premalignancy-
speciﬁc effector T cells in patients with monoclonal gammopathy,7
the phenomenon of ‘plateau phase’ where despite a signiﬁcant
residual tumour burden the disease does not progress8 and the
association between the presence of expanded T-cell clones and
an improved survival.9–11 We hypothesised that patients with
myeloma who are long-term survivors (LTS-MM) have greater
immunocompetence and that a study of immune biomarkers in
these LTS-MM patients might provide a novel approach to
understanding the mechanisms of immune dysfunction in MM.
Expanded T-cell clones have been reported to be present in the
blood of patients with MM,9–11 Waldenstrom’s macroglobulinemia,12
chronic myeloid leukemia13 and myelodysplastic syndromes.14,15
The incidence in patients with MM was 48% in a national clinical
trial (n¼ 120)10 and 54% in our single institution cohort (n¼ 144).9
These expanded T-cell clones have the immunophenotype of
effector memory T cells (CD3þCD8þCD57þ ), have a restricted
T-cell receptor (TCR) Vb expression and comprise up to 50%
of the total T-cell population.9–11,16,17 As representative TCR
Vb-restricted expansions from both patients with MM and
Waldenstrom’s macroglobulinemia have all been proven to be
clonal by sequencing TCR CDR3 hypervariable regions, it can be
considered that the detection of all expanded TCR Vb-restricted
populations are associated with a T-cell clone.12,16,17 Clonal
expansions of cells with an effector memory T-cell phenotype
have been associated with chronic antigen stimulation in the
setting of persistent viral infection.18 However, in the MM cohorts
studied, there was a lack of association with any common viral
serology or cytomegalovirus pp65 tetramer staining, suggesting
that chronic stimulation by a non-viral antigen is involved.16,17
Furthermore, neither idiotype- nor cancer germline-speciﬁc
tetramers have identiﬁed the speciﬁcity of these clones, as such
tetramer-positive cells are rarely more than 0.1% of the T-cell
population.16,19 Expanded T-cell clones are clinically relevant as
they are strongly associated with improved outcomes in MM,10,16
their incidence increases with exposure to thalidomide and their
presence is associated with prolonged remission in patients
receiving maintenance thalidomide after autologous
transplantation.10 Identiﬁcation of the speciﬁcity of expanded
T-cell clones has been restricted as they fail to respond in either
proliferation or cytotoxicity assays, suggesting that these cells are
predominantly anergic.12
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Although the presence of T-cell clones has prognostic
signiﬁcance, changes in other clinically signiﬁcant immune
biomarkers such as T-regulatory cells (Tregs) should also be
considered. The balance between the suppressive Treg cells and
pro-inﬂammatory T helper 17 (Th17) cells is a major factor in
immunoregulatory control20–22 and although there is considerable
variation between reports of the number of Treg cells in patients
with MM, this can be attributed to technical differences in assay
methodology and patient selection.23,24
We hypothesise that the immune function of LTS-MM patients is
different from other patients with MM and that an analysis of
immune biomarkers may provide novel opportunities to identify
good prognosis patients, further characterise the immune
dysfunction associated with MM and reveal insights for immune-
based therapies. We analysed the number of cytotoxic T-cell
clones and their ability to proliferate and secrete cytokines, as well
as the balance between suppressive Tregs and pro-inﬂammatory
Th17 cells. These immune biomarkers were determined in LTS-MM
patients, MM patients with shorter follow-up and a group of
age-matched controls. Differences in all parameters were evident,
demonstrating that long-term survival is associated with a distinct
immunological proﬁle suggestive of less immune suppression.
MATERIALS AND METHODS
Patients, controls and samples
All patients attending our clinic for 410 years from diagnosis of MM and
who had required treatment were identiﬁed and included in the study
group (n¼ 20). These patients represent approximately 5% of the total
patients attending the clinic. Sample collection and clinical record review
were performed with informed consent in accordance with the Declaration
of Helsinki. The frequency of T-cell clones was compared with two large
cohorts of MM patients, one composed of patients collected sequentially
at our clinic (n¼ 144)9 and another of patients (n¼ 120) enrolled in a
national clinical trial investigating the role of maintenance thalidomide,
with samples collected before randomisation.10 Results for the T-cell clone
proliferation assay, Treg and Th17 cell analysis were compared with
sequentially acquired MM patients attending our clinic and a group of age-
matched controls with normal haematological parameters and no known
medical abnormality.
Flow cytometry analysis
All studies were performed on EDTA-anticoagulated peripheral blood
samples, which were prepared by Ficoll Paque (GE Healthcare, Uppsala,
Sweden) centrifugation and cryopreserved for later analysis. All ﬂow
cytometry was performed on a BD FACS ARIA II (BD Biosciences, San Jose,
CA, USA). T-cell clonal expansions were detected using TCRVb repertoire
analysis using an IOTest Beta Mark TCRVb Repertoire Kit (Beckman Coulter,
Brea, CA, USA) as previously described.10–12,15–17 TCRVbþ clones were
identiﬁed by the overexpression of one TCRVb family. This was deﬁned as
greater than the mean plus 3 standard deviations of the TCR Vb analysis of
42 age-matched controls for each TCRVb family. We have previously
conﬁrmed the clonality of these expansions by sequencing CDR3
hypervariable regions.12,16,17 TCRVb panels included antibodies to CD3,
CD8 and CD57 (BD Biosciences) and antibodies to speciﬁc TCR Vb families
(Beckman Coulter). The phenotype of T-cell clones is CD3þCD8þCD57þ in
493% of cases. Tregs were deﬁned as CD3þCD4þCD25þ þCD127lo cells
as previously described.25 Th17 cells were detected as CD3þCD4þ cells
secreting IL17 (anti-IL17; BD Biosciences) after incubation with phorbol
myristate acetate, ionomycin and brefeldin according to manufacturer’s
instructions and interferon-g expression was determined with anti-
interferon-g (BD Biosciences).
T-cell sorting and proliferation assay
T-cell clones were sorted on a BD FACS ARIA II (BD Biosciences) as shown
(Figure 1c). The proliferation of sorted clonal and non-clonal T-cells was
measured using carboxyﬂuorescein succinimidyl ester (CFSE) tracking. In
brief, 1 105 T cells from each individual were labelled with 5 mM CFSE
using CellTrace CFSE Cell Proliferation Kit (Life Sciences, Carlsbad, CA, USA),
cultured in RPMI 10 and stimulated with anti-CD3 and anti-CD28 beads
(Miltenyi Biotech, Bergisch Gladbach, Germany) at a ratio of 1:1 for 4 days.
At this point, proliferation was measured as the proportion of cells that had
passed through Z1 division.
Statistical analysis
Statistical analysis involving the Mann–Whitney (U) and Student’s t-test
was performed as appropriate for parametric and non-parametric data
using GraphPad PRISM v5.01 (GraphPad Software, La Jolla, CA, USA).
RESULTS
Clinical characteristics of LTS-MM patients
There were 20 patients attending our clinic 410 years after a
diagnosis of symptomatic MM. Table 1 displays the clinical
characteristics of the LTS-MM cohort and the cohorts of MM
patients used to compare the proliferation of T-cell clones, Treg
frequency and Th17 cell frequency. The frequency of clonal T-cell
expansions was compared with patients tested in the context of a
clinical trial (n¼ 120), with a similar median age and International
Staging System (ISS) risk group at diagnosis,10,26 and a large local
cohort of MM patients as previously published (n¼ 144).9 As all
LTS-MM patients were diagnosed 410 years ago, there is little
ﬂuorescence in situ hybridization data available, and treatment
was predominantly with multi-agent chemotherapy as novel
agents were not widely available at that time. The entire LTS-MM
cohort is included even though samples were not available for all
tests to be performed. Two patients have recently relapsed and
died.
LTS-MM is associated with an increased frequency of T-cell clonal
expansions
We have identiﬁed T-cell clones in two previous cohorts of MM
patients and found their incidence to be 48% (n¼ 120) and 54%
(n¼ 144).9,23,24 In comparison, T-cell clones were found in 100%
(n¼ 19/19) of the LTS-MM patients tested, accounting for a median
of 14.9% of CD3þ cells. There was no clear over-representation of
any particular TCR Vb subfamily. A representative analysis of a MM
sample is shown in Figures 1a and b. In this case, there is an
expanded TCRV b13.1 population.
T-cell clonal expansions in LTS-MM lack the anergy found in
patients with MM
T-cell clones of patients with MM had a low proliferative capacity
in vitro in 4-day CFSE assays, whereas the non-clonal T cells in
these patients were highly proliferative (U¼ 0.0, Po0 0.0001;
Figure 2a). In contrast, the T-cell clones in the LTS-MM patients
had a high proliferative capacity, similar to autologous non-clonal
T cells (Figure 2a). The median proliferation of the T-cell clones
was 61.5% (n¼ 15) for the LTS-MM patients compared with 6.1%
(n¼ 10) for MM patients (U¼ 6.0, Po0.0001; Figure 2a). Interferon-
g production was not signiﬁcantly different in the T-cell clones of
the MM and LTS-MM patients (Figure 2b).
T-cell clones remain in the blood of LTS-MM patients for long
periods
Eight of the LTS-MM patients had serial blood samples tested for
T-cell clones over an interval of more than 10 years. For seven of
these eight patients, the same expanded TCR Vb family persisted
for more than 10 years.
The Treg/Th17 balance is abnormal in MM and is more favourable
in LTS-MM
Treg and Th17 cell numbers were analysed in the peripheral
blood. Representative ﬂow plots of the analysis of CD3þ CD4þ
CD25þ þ CD127- Tregs (Figure 3a) and CD3þ CD4þ IL-17þ Th17
cells (Figure 3b) are shown. MM patients had a decreased absolute
CD4 count and there was no signiﬁcant difference in the CD4
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count between the MM and LTS-MM patients (Figure 3c). Tregs
were increased in the blood of MM patients compared with age-
matched healthy control donors (Figure 3d), when expressed
as a percentage of CD4þ T cells. Tregs were decreased in
LTS-MM patients (n¼ 16) when compared with MM patients
(n¼ 30), whether expressed as a percentage of CD4þ -cells
(t¼ 3.01; Po0.005) or as an absolute number (U¼ 155; Po0.02;
Figures 3d–e). Th17 cells were decreased in MM patients (n¼ 12)
when expressed as an absolute number (U¼ 2.49; Po0.02) but
not signiﬁcantly different from controls when expressed as a
percentage of T cells. Th17 cells were, however, increased in
LTS-MM patients when compared with MM patients whether
expressed as a percentage (U¼ 19; Po0.005) or an absolute
number (U¼ 48; Po0.05; Figures 3f–g).
The Treg/Th17 ratio (Figure 3h) was increased in MM patients,
however, it was signiﬁcantly lower in the LTS-MM patients and
similar to the control group (U¼ 8.0; Po0.001). The Treg/Th17
ratio may be the best discriminator of immunoregulatory control,
as it indicates the balance of suppressive and pro-inﬂammatory
regulatory cells.
DISCUSSION
We have identiﬁed a group of patients with symptomatic MM
attending a single clinic who survived for 410 years. We have
assayed a range of immunological biomarkers in their peripheral
blood samples to assess whether speciﬁc immune features are
associated with longer survival. We have provided evidence
Figure 1. The detection of clonal expansions of T cells using flow cytometry to measure TCR Vb subfamily overexpression. (a) Representative
flow scattergrams and (b) bar graph demonstrating a clonal expansion of Vb family 13.1 and (c) the gating strategy utilised for T-cell clone
sorting. In this example, a TCR Vb1 expansion was detected from CD3þCD8þ region. The TCRV b1 expansion had both CD57þ and CD57-
subpopulations. PE, phycoerythrin.
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that this group of patients have a range of immunological
biomarkers, which are different from other patients with MM.
The major ﬁndings reported here are: ﬁrst, that all LTS-MM
patients analysed had expanded cytotoxic T-cell clones present,
and unlike the majority of patients with MM, the T-cell clones
in LTS-MM patients respond to stimulation by proliferating
and producing cytokines, and second, the Treg/Th17 ratio,
which is increased in MM patients, is not increased in LTS-MM
patients.
There are clear demographic differences between the LTS-MM
group (Table 1) and the comparison cohorts. It is predictable that
the LTS group will contains fewer males and have lower measures
of tumour bulk at diagnosis, as these measures are associated with
longer survival in MM. However, despite this, all groups contained
patients predominantly in the lowest ISS risk category. Similarly,
differences in therapy between the groups are understandable
given the fact that most LTS-MM patients received treatment410
years ago, and the management of MM has changed considerably
over that time. Possibly, the most signiﬁcant difference is in
treatment with novel agents, and this is predominantly accounted
for by thalidomide, with low exposure in the LTS-MM group. As
thalidomide enhances the proliferation of T cells in vitro,27 this
Figure 2. The proliferation and cytokine production of T-cell clones.
Cells were tracked with CFSE after stimulation with anti-CD3 and
anti-CD28 beads for 4 days. Proliferation was assessed as the % cells
that progressed through at least one cell division. (a) Proliferation of
clonal T cells from LTS-MM patients and MM patients (Po0.001) and
the respective non-clonal T cells. (b) Interferon-g production in
clonal and non-clonal T cells from LTS-MM patients and MM patients
(P¼not significant).
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does not explain the observed increase in proliferation of T-cell
clones in LTS-MM patients. Thalidomide has also been shown to
increase Treg number in MM. Although there was higher exposure
in the MM group than the LTS-MM group (57% and 25%,
respectively), few (17% and 6%, respectively) were taking it at the
time of testing, and its propensity to increase Tregs is seen mainly
during treatment.28
We have attempted to expand T-cell clones from MM patients
in vitro but have consistently found them to have low or no
proliferative response despite normal proliferation of other
T cells from the same patient (Figure 2a). As ex vivo expansion of
these cells may provide a potential therapeutic intervention, we
have attempted to overcome their anergy through the use of a
broad panel of stimulatory cytokines and antibodies, which
enhance proliferation. However, this has not yet been possible
(data not shown). As these T-cell clones retain the ability to secrete
interferon-g despite a lack of proliferation (Figure 2b), we suggest
that T-cell clones in patients with MM exist in a state of split
anergy.29 This anergic state may be induced by regulatory T cells,
which can suppress anti-tumour cytotoxic T-cell responses but not
interferon-g production through transforming growth factor b
(TGFb) signalling.30
Figure 3. Analysis of Tregs and Th17 cells. Representative flow scattergrams demonstrating the identification of (a) Tregs as CD3þCD4þ
CD25þ þ and CD127- and (b) Th17 cells as CD4þ IL-17þ . The comparison of results from LTS-MM, MM and healthy donor controls for
(c) absolute CD4 count. (d) Percentage Tregs. (e) Absolute Tregs. (f ) Percentage Th17 cells. (g) Absolute Th17 cells. (h) Treg/Th17 ratio. NS, not
significant.
Immune biomarkers in 10-year survivors of myeloma
C Bryant et al
5
& 2013 Macmillan Publishers Limited Blood Cancer Journal
We recently published observations that suggest that multiple
abnormalities cause the anergy in T-cell clones of patients with
MM and Waldenstrom’s macroglobulinemia.12 We performed
gene set-enrichment analysis after microarray of ﬂow-sorted clonal
and non-clonal CD8þ T cells and demonstrated upregulation of a
number of signalling pathways. This included the RAS pathway, and
upregulated expression of Ras, BCL2L1 (BCL-XL) and CHUK (IKK) could
inhibit apoptosis in the expanded T cells, thus allowing their
long-term persistance.31 An upregulated CSK pathway would
recruit CREBBP to activate CSK and inhibit T-cell activation.32
An upregulated TOB pathway, in which TGFB could activate SMADs
to interact with Tob and maintain an unstimulated T cell.33 TGFB
could also engage with TGFBR, CDKN2A (p16) within a G1/S
transition pathway to downregulate CCND2 and CDK6, leading to
cell cycle G1/S transition arrest.34 Finally, upregulation of PTPN7
(HePTP) expression could lead to a suppression of T-cell
proliferation by inactivating ERK.35 Although this microarray data
suggest that multiple mechanisms contribute to T-cell anergy, the
neutralisation of TGFb may be a key factor in the dysfunction of
both T cells.36
Tregs are instrumental in the maintenance of tolerance to self-
antigens. They suppress low-afﬁnity self-reactive T-cells, which
escape negative selection in the thymus, but in doing so may also
impair tumour-speciﬁc immune responses. Tregs induce anergy in
tumour-speciﬁc CD8 T-cells through multiple mechanisms37 and
increased Treg numbers are associated with worse outcomes in
MM38 and in solid organ malignancies.39–41 We and others have
found Tregs to be increased in MM patients42,43 and we now report
that they are signiﬁcantly lower in LTS-MM patients44 indicating a
less tolerogenic immune environment.
Th17 cells have a well-established role in the promotion of
auto-inﬂammation45 and they promote the survival of tumour-
reactive T-cells in the context of malignancy.46 Although bone
marrow Th17 cells support MM cell growth47 and bone disease,48
the balance of Treg/Th17 cells also regulates auto-reactive
immune responses. The consideration of peripheral blood Treg
and Th17 numbers may provide a better indication of the
regulatory cell involvement than a determination of Treg cells
alone. Th17 cell numbers were signiﬁcantly increased in LTS-MM
patients and interestingly, although the Treg/Th17 ratio was
markedly increased in MM patients, it was decreased in
LTS-MM patients when compared with MM and even controls.
This suggests a fundamental difference in the T-cell helper
environment in LTS-MM patients.
In conclusion, LTS-MM patients have a distinct immunological
proﬁle. This includes an improved Treg/Th17 balance and an
increased incidence of persistent T-cell clonal expansions which,
unlike those found in other MM patients, are proliferative. These
features suggest that patients who survive MM long term have
decreased immune suppression.
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